Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.

Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB.

PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245. Epub 2012 Jul 10.

2.

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study.

Hontelez JA, Lurie MN, Bärnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell ML, de Vlas SJ.

PLoS Med. 2013 Oct;10(10):e1001534. doi: 10.1371/journal.pmed.1001534. Epub 2013 Oct 22.

3.

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB.

AIDS. 2013 Jan 28;27(3):447-58. doi: 10.1097/QAD.0b013e32835ca2dd.

PMID:
23296196
4.

The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models.

Pretorius C, Menzies NA, Chindelevitch L, Cohen T, Cori A, Eaton JW, Fraser C, Gopalappa C, Hallett TB, Salomon JA, Stover J, White RG, Dodd PJ.

AIDS. 2014 Jan;28 Suppl 1:S25-34. doi: 10.1097/QAD.0000000000000085.

PMID:
24468944
5.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

6.

Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050.

Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG.

PLoS One. 2012;7(2):e30216. doi: 10.1371/journal.pone.0030216. Epub 2012 Feb 13.

7.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration..

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

8.

The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.

Ross E, Tanser F, Pei P, Newell ML, Losina E, Thiebaut R, Weinstein M, Freedberg K, Anglaret X, Scott C, Dabis F, Walensky R.

HIV Clin Trials. 2014 Sep-Oct;15(5):185-98. doi: 10.1310/hct1505-185.

9.

Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era.

Eaton JW, Bacaër N, Bershteyn A, Cambiano V, Cori A, Dorrington RE, Fraser C, Gopalappa C, Hontelez JA, Johnson LF, Klein DJ, Phillips AN, Pretorius C, Stover J, Rehle TM, Hallett TB.

Lancet Glob Health. 2015 Oct;3(10):e598-608. doi: 10.1016/S2214-109X(15)00080-7.

10.

Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.

Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW.

J Infect Dis. 2013 Jul 15;208(2):224-34. doi: 10.1093/infdis/jit150. Epub 2013 Apr 9.

11.

Setting ART initiation targets in response to changing guidelines: The importance of addressing both steady-state and backlog.

Martin C, Naidoo NP, Venter WD, Jaffer A, Barker PM.

S Afr Med J. 2014 May 12;104(6):428-30. doi: 10.7196/samj.7507.

PMID:
25214253
12.

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Lawn SD, Myer L, Edwards D, Bekker LG, Wood R.

AIDS. 2009 Aug 24;23(13):1717-25. doi: 10.1097/QAD.0b013e32832d3b6d.

13.

Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.

Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, Fox MP, Wood R, Prozesky H, Giddy J, Garone DB, Cornell M, Egger M, Boulle A; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration..

PLoS Med. 2013;10(4):e1001418. doi: 10.1371/journal.pmed.1001418. Epub 2013 Apr 9.

14.

Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.

Smith JA, Sharma M, Levin C, Baeten JM, van Rooyen H, Celum C, Hallett TB, Barnabas RV.

Lancet HIV. 2015 Apr;2(4):e159-68.

15.

Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis.

Dodd PJ, Knight GM, Lawn SD, Corbett EL, White RG.

PLoS One. 2013 Sep 17;8(9):e75466. doi: 10.1371/journal.pone.0075466. eCollection 2013.

16.

The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.

Meyer-Rath G, Pienaar J, Brink B, van Zyl A, Muirhead D, Grant A, Churchyard G, Watts C, Vickerman P.

PLoS Med. 2015 Sep 1;12(9):e1001869. doi: 10.1371/journal.pmed.1001869. eCollection 2015 Sep.

17.

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators..

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.

18.

Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis.

Chindelevitch L, Menzies NA, Pretorius C, Stover J, Salomon JA, Cohen T.

J R Soc Interface. 2015 May 6;12(106). pii: 20150146. doi: 10.1098/rsif.2015.0146.

19.

Prospects for HIV control in South Africa: a model-based analysis.

Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, Boulle A, Meyer-Rath G.

Glob Health Action. 2016 Jun 8;9:30314. doi: 10.3402/gha.v9.30314. eCollection 2016.

20.

The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.

Hontelez JA, de Vlas SJ, Tanser F, Bakker R, Bärnighausen T, Newell ML, Baltussen R, Lurie MN.

PLoS One. 2011;6(7):e21919. doi: 10.1371/journal.pone.0021919. Epub 2011 Jul 20.

Supplemental Content

Support Center